GlassScriptPhysician profile
Ana M Eduardo
NPI 1205809654
$17,132.93
in general payments reported to CMS, 2019-2025
43 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $325 · 2021: $1,345 · 2022: $1,098 · 2023: $13K · 2024: $454 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $1,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,000.00 |
| Food and Beverage | $1,591.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $12,383.67 | 2019-2025 | Slynd |
| Abbvie INC. | $1,132.79 | 2019-2024 | Lo Loestrin Fe, Liletta, Orilissa |
| Mayne Pharma Commercial LLC | $473.62 | 2021-2025 | |
| Hologic Sales and Service, LLC | $405.89 | 2019-2025 | Acessa Provu System, Aptima, Myosure Tissue Removal Device |
| Coopersurgical, INC. | $293.03 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Lupin INC. | $210.99 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $202.41 | 2019-2020 | |
| Evofem Biosciences, INC. | $172.49 | 2020-2024 | Phexxi |
| Astellas Pharma US INC | $168.00 | 2021-2025 | Veozah, Myrbetriq |
| Myovant Sciences INC. | $144.97 | 2022 | |
| Axonics, INC. | $135.72 | 2022-2023 | Axonics |
| Intuitive Surgical, INC. | $134.22 | 2019-2022 | |
| Agile Therapeutics, INC. | $115.15 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $102.18 | 2022 | |
| Pfizer INC. | $98.62 | 2019-2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $94.91 | 2019-2022 | |
| Conmed Corporation | $83.33 | 2021 | |
| Sumitomo Pharma America, INC. | $73.72 | 2024-2025 | Gemtesa, Myfembree |
| Exact Sciences Corporation | $64.45 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $58.14 | 2019-2020 | |
| Organon LLC | $56.56 | 2022-2024 | |
| Duchesnay USA Incorporated | $51.84 | 2019 | |
| Merck Sharp & Dohme LLC | $51.51 | 2019-2021 | |
| Biogen, INC. | $39.74 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $38.83 | 2025 | |
| Dysis Medical, INC. | $34.77 | 2021 | |
| Millicent US INC | $33.43 | 2020-2023 | Intrarosa |
| Minerva Surgical, INC | $29.41 | 2019-2025 | |
| Gynesonics, INC. | $27.73 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Endo Pharmaceuticals INC. | $25.47 | 2019 | |
| Boston Scientific Corporation | $25.10 | 2025 | Axonics |
| Baxter Healthcare | $23.43 | 2021 | |
| Novo Nordisk INC | $23.27 | 2025 | Wegovy |
| Genentech USA, INC. | $20.49 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.50 | 2019 | |
| Meditrina | $16.78 | 2022 | |
| Mylan Pharmaceuticals INC. | $15.76 | 2020 | |
| Therapeuticsmd, INC. | $14.78 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $13.53 | 2023 | Exparel |
| Davol INC. | $13.51 | 2022 | |
| Aspira Women'S Health INC | $10.19 | 2024 | Ova1 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Eduardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.